EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling

William C Arnold, Durga Meenakshi Panneerdoss, Baskaran Subramani iD, Megharani Mahajan, Behnam Ebrahimi, Paulina Ramirez, Bindu Santhamma, Suryavathi Viswanadhapalli iD, Edward R Kost, Yidong Chen, Zhao Lai, Hareesh B Nair iD und 2 weitere

Biomolecules · 2025

DOI: 10.3390/biom15101396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von William C Arnold und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Hauptthemen laut MEDLINE: Pyrimidinones, Pyridones, Ovarian Neoplasms, Leukemia Inhibitory Factor Receptor alpha Subunit. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OCa) remains the most lethal gynecologic malignancy in the United States, with low-grade serous and mucinous subtypes frequently driven by KRAS mutations. These mutations activate downstream MAPK and PI3K/AKT signaling pathways, contributing to tumor progression and resistance to therapy. Although the MEK inhibitor trametinib is used to target these pathways, its efficacy is limited in KRAS-mutant OCa due to compensatory activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) axis. In this study, we evaluated the therapeutic potential of combining trametinib with EC359, a selective LIFR inhibitor, in Ras/Raf-driven OCa models. EC359 significantly reduced cell viability, clonogenic survival, and induced cell death via ferroptosis in vitro. Mechanistic studies revealed that EC359 suppressed trametinib-induced activation of LIFR downstream signaling. RNA-seq analysis showed that combination therapy downregulated mitochondrial translation and MYC target genes while upregulating apoptosis-related genes. In vivo, EC359 and trametinib co-treatment significantly reduced tumor growth in xenograft and PDX models without inducing toxicity. Our studies identify LIFR signaling as a critical vulnerability in Ras/Raf-mutant and low grade serous OCa. Further, it provides strong preclinical rationale for EC359 and trametinib combination therapy as a new therapeutic strategy for treating Ras/Raf-driven OCa and low-grade serous OCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinonesPyridonesOvarian NeoplasmsLeukemia Inhibitory Factor Receptor alpha SubunitProto-Oncogene Proteins p21(ras)raf KinasesFemaleHumansAnimalsSignal TransductionMiceCell Line, TumorXenograft Model Antitumor Assaysras ProteinsCell Survival

Stichwörter der Autor:innen

EC359LIFRMAPKRas/Raf mutationsSTAT3low grade serous ovarian cancerovarian cancertrametinib

Substanzen

trametinibPyrimidinonesPyridonesLeukemia Inhibitory Factor Receptor alpha SubunitLIFR protein, humanProto-Oncogene Proteins p21(ras)raf Kinasesras ProteinsKRAS protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Evestra, Inc., San Antonio, TX 78245, USA.
  • Mays Cancer Canter, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Greehey Children's Cancer Research Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Department of Population Health Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
  • Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA.

ORCID-Profile: Baskaran Subramani, Suryavathi Viswanadhapalli, Hareesh B Nair, Ratna K Vadlamudi

Förderung

  • NCI NIH HHS
  • NIH HHS
  • BLRD VA
  • UT Health Mays Cancer center
  • MCC Pilot grant
  • AstraZeneca Young Investigator award
  • Cancer Center at UT Health San Antonio
  • NIH Shared Instrumentation

Zitieren

APA

Arnold, W. C., Panneerdoss, D. M., Subramani, B., Mahajan, M., Ebrahimi, B., Ramirez, P., Santhamma, B., Viswanadhapalli, S., Kost, E. R., Chen, Y., Lai, Z., Nair, H. B., Vadlamudi, R. K., & Lyons, Y. A. (2025). EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling. Biomolecules. https://doi.org/10.3390/biom15101396

Vancouver

Arnold WC, Panneerdoss DM, Subramani B, Mahajan M, Ebrahimi B, Ramirez P, et al. EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling. Biomolecules. 2025. doi:10.3390/biom15101396

BibTeX
@article{Arnold2025,
  author = {Arnold, William C and Panneerdoss, Durga Meenakshi and Subramani, Baskaran and Mahajan, Megharani and Ebrahimi, Behnam and Ramirez, Paulina and Santhamma, Bindu and Viswanadhapalli, Suryavathi and Kost, Edward R and Chen, Yidong and Lai, Zhao and Nair, Hareesh B and Vadlamudi, Ratna K and Lyons, Yasmin A},
  title = {EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15101396}
}
Kostenlos starten →